The purpose of this study is to assess the safety and efficacy of enzalutamide in patients with non metastatic prostate cancer.
The investigators aim to evaluate the feasibility of a larger clinical trial assessing an exercise program during the "teachable moment" in patients with prostate cancer and measuring its effect on tumor apoptosis signaling, lipogenesis and steroidogenesis. Participants will be randomized between a 8-12 week exercise program or to standard of care only. Participants will be assessed at screening, baseline (day 0), throughout the trial intervention (days 1-84), post-intervention visit (prior to radical prostatectomy) and final study visit 6-months post-radical prostatectomy.
Prostate cancer treatments are known to impact sexual lives of men and their partners. Although treatments do exist to help rehabilitate sexual functioning, approximately 50% of people stop using these treatments after 6 months. Researchers at UBC and the Prostate Cancer Centre are developing a new treatment using mindfulness-based therapy to help couples cope with the changes that prostate cancer bring to their lives.
We are conducting a study in order to prospectively track the sexual outcomes of men after their prostate cancer treatment.
To collect saliva samples from men who are currently or were previously on active surveillance to try and identify genetic factors that could suggest how aggressive their prostate cancer could be. This is part of a larger study led by Dr. William Catalona at Northwestern University, Chicago.
The purpose of this study is to compare the radiographic progression-free survival (rPFS) of JNJ56021927 in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of sperm]).
The purpose of this study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have high-risk prognostic factors will benefit from the addition of abiraterone acetate and low-dose prednisone to androgen deprivation therapy (ADT; lutenizing hormone releasing hormone [LHRH] agonists or surgical castration).
The purpose of the study is to test the impact of a novel intervention to promote healthy nutrition and weight control for prostate cancer survivors and their partners
The purpose of this study is to evaluate the efficacy and safety of ARN-509 in adult men with high-risk non-metastatic castration-resistant prostate cancer.
This project will develop and evaluate a treatment plan for prostate focal therapy based on low dose rate brachytherapy. The participants entering this study are those suitable for active surveillance. These participants will be monitored with various imaging methods and interventions such as MR elastography, Transrectal ultrasound elastography, PET/CT and transperineal mapping biopsy to determine the extent of cancer and suitable treatments.